Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentamidine + ICE in Relapsed/Refractory Classical Hodgkin Lymphoma
NCT03730363Phase 1Completed
- Start
- Dec 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pentamidine in Classical Hodgkin Lymphoma (cHL). Primary endpoint: Maximum Tolerated Dose at 21 days. Started Dec 2018; status: completed.
02
Drugs
pentamidine
03
Conditions
Classical Hodgkin Lymphoma (cHL)
Beyond the preview
Go deeper on NCT03730363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03730363.